Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma

The impact of improved treatment strategies on overall survival in glioblastoma patients

(2013) P. J. Slotty et al.   ACTA NEUROCHIRURGICA

Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53

(2013) Mourad Sanhaji et al.   CELL CYCLE

Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer

(2012) V. Maire et al.   CANCER RESEARCH

A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non–Small-Cell Lung Cancer

(2012) Peter M. Ellis et al.   Clinical Lung Cancer

Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours

(2012) A. Frost et al.   Current Oncology

Polo-Like Kinase 1 Inhibition Kills Glioblastoma Multiforme Brain Tumor Cells in Part Through Loss of SOX2 and Delays Tumor Progression in Mice

(2012) Cathy Lee et al.   STEM CELLS

Switching Polo-like kinase-1 on and off in time and space

(2012) Wytse Bruinsma et al.   TRENDS IN BIOCHEMICAL SCIENCES

Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo

(2011) Xianzhe Liu et al.   ANTI-CANCER DRUGS

Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer

(2011) N. Syed et al.   CANCER RESEARCH

Glioblastoma multiforme with very rapid growth and long-term survival in children: report of two cases and review of the literature

(2011) Mahmoud Reza Khalatbari et al.   CHILDS NERVOUS SYSTEM

Antiproliferative in vitro effects of BI 2536-mediated PLK1 inhibition on cervical adenocarcinoma cells

(2011) Julia A. Pezuk et al.   CLINICAL AND EXPERIMENTAL MEDICINE

Upregulation of Polo-like kinase 2 gene expression by GATA-1 acetylation in human osteosarcoma MG-63 cells

(2011) Tao Shen et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

The proliferation rate paradox in antimitotic chemotherapy

(2011) Timothy J. Mitchison   MOLECULAR BIOLOGY OF THE CELL

Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity

(2011) Ravichandran N. Murugan et al.   MOLECULES AND CELLS

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

(2010) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial

(2010) Martin Sebastian et al.   Journal of Thoracic Oncology

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

(2010) Klaus Strebhardt   NATURE REVIEWS DRUG DISCOVERY

Plk4 is required for cytokinesis and maintenance of chromosomal stability

(2010) C. O. Rosario et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Treatment of biliary tract cancer with NVP-AEW541: Mechanisms of action and resistance

(2010) Samuel Wolf   WORLD JOURNAL OF GASTROENTEROLOGY

Advances in the Treatment of Malignant Gliomas

(2010) Mustafa Khasraw et al.   Current Oncology Reports

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells

(2009) A. G. Renner et al.   BLOOD

Selection of suitable housekeeping genes for expression analysis in glioblastoma using quantitative RT-PCR

(2009) Valeria Valente et al.   BMC MOLECULAR BIOLOGY

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics

(2009) Puneet Chopra et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Polo-Like Kinase 1 Depletion Induces DNA Damage in Early S Prior to Caspase Activation

(2009) H. Yim et al.   MOLECULAR AND CELLULAR BIOLOGY

Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas

(2009) K. Hu et al.   MOLECULAR CANCER THERAPEUTICS

Polo-like kinases: conservation and divergence in their functions and regulation

(2009) Vincent Archambault et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Death through a tragedy: mitotic catastrophe

(2008) H Vakifahmetoglu et al.   CELL DEATH AND DIFFERENTIATION

Glioblastoma in adults

(2008) Alba A. Brandes et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY